Published by Josh White on 29th January 2026
(Sharecast News) - Sanofi reported strong fourth-quarter and full-year results for 2025 on Thursday, underpinned by robust growth from its blockbuster asthma and dermatology treatment Dupixent, while forecasting another year of profitable growth in 2026 despite lingering concerns over its pipeline and vaccine demand.